Grace Therapeutics, Inc.

GRCE

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

None scheduled

Drug Pipeline

Drug Name	Phase	Indication	Designations
GTX-104	Phase 3	Aneurysmal Subarachnoid Hemorrhage (aSAH)	-
CaPre	Phase 3	Hypertriglyceridemia	-
Placebo	Phase 3	Hypertriglyceridemia	-
Lipid Lowering Medication	Phase 2	Hypertriglyceridemia	-
CaPre (TM)	Phase 2	Hypertriglyceridemia	-

Catalyst Timeline

0 upcoming, 0 past

No catalysts found.

Regulatory Approvals

GRCE News